Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.

Ma G, Gezer D, Herrmann O, Feldberg K, Schemionek M, Jawhar M, Reiter A, Brümmendorf TH, Koschmieder S, Chatain N.

Mol Carcinog. 2019 Nov 6. doi: 10.1002/mc.23131. [Epub ahead of print]

PMID:
31691359
2.

Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies.

Ferreira MSV, Kirschner M, Halfmeyer I, Estrada N, Xicoy B, Isfort S, Vieri M, Zamora L, Abels A, Bouillon AS, Begemann M, Schemionek M, Maurer A, Koschmieder S, Wilop S, Panse J, Brümmendorf TH, Beier F.

Ann N Y Acad Sci. 2019 Oct 24. doi: 10.1111/nyas.14248. [Epub ahead of print]

PMID:
31647584
3.

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.

Herrmann O, Kuepper MK, Bütow M, Costa IG, Appelmann I, Beier F, Luedde T, Braunschweig T, Koschmieder S, Brümmendorf TH, Schemionek M.

BMC Cancer. 2019 Jul 4;19(1):658. doi: 10.1186/s12885-019-5871-2.

4.

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha.

Schubert C, Allhoff M, Tillmann S, Maié T, Costa IG, Lipka DB, Schemionek M, Feldberg K, Baumeister J, Brümmendorf TH, Chatain N, Koschmieder S.

J Hematol Oncol. 2019 Apr 2;12(1):36. doi: 10.1186/s13045-019-0722-9.

5.

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.

Kuepper MK, Bütow M, Herrmann O, Ziemons J, Chatain N, Maurer A, Kirschner M, Maié T, Costa IG, Eschweiler J, Koschmieder S, Brümmendorf TH, Müller-Newen G, Schemionek M.

Leukemia. 2019 Aug;33(8):1964-1977. doi: 10.1038/s41375-019-0427-7. Epub 2019 Mar 6.

PMID:
30842608
6.

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS.

Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10.

PMID:
30530751
7.

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH.

Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772.

8.

Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.

Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, Blau W, Kreuter M, Rosewich M, Corbacioglu S, Beck J, Schwarz M, Bittenbring J, Radsak MP, Wilk CM, Koschmieder S, Begemann M, Kurth I, Schemionek M, Brümmendorf TH, Beier F.

Leukemia. 2018 Aug;32(8):1762-1767. doi: 10.1038/s41375-018-0125-x. Epub 2018 Apr 2.

PMID:
29749397
9.

Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.

Ventura Ferreira MS, Crysandt M, Ziegler P, Hummel S, Wilop S, Kirschner M, Schemionek M, Jost E, Wagner W, Brümmendorf TH, Beier F.

Ann Hematol. 2017 Sep;96(9):1457-1461. doi: 10.1007/s00277-017-3049-z. Epub 2017 Jul 3.

PMID:
28674830
10.

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients.

Schubert C, Chatain N, Braunschweig T, Schemionek M, Feldberg K, Hoffmann M, Dufva O, Mustjoki S, Brümmendorf TH, Koschmieder S.

Oncotarget. 2017 May 23;8(21):34736-34749. doi: 10.18632/oncotarget.16152.

11.

Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion.

Fahrenkamp D, Herrmann O, Koschmieder S, Brümmendorf TH, Schemionek M.

Leukemia. 2017 Apr;31(4):1017-1019. doi: 10.1038/leu.2017.19. Epub 2017 Feb 7. No abstract available.

PMID:
28167834
12.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS.

Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

13.

Tumor Suppressor Analysis in CML.

Herrmann O, Schemionek M.

Methods Mol Biol. 2016;1465:87-94. doi: 10.1007/978-1-4939-4011-0_8.

PMID:
27581141
14.

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.

Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N.

J Hematol Oncol. 2016 May 13;9(1):45. doi: 10.1186/s13045-016-0275-0.

15.

Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Schemionek M, Herrmann O, Reher MM, Chatain N, Schubert C, Costa IG, Hänzelmann S, Gusmao EG, Kintsler S, Braunschweig T, Hamilton A, Helgason GV, Copland M, Schwab A, Müller-Tidow C, Li S, Holyoake TL, Brümmendorf TH, Koschmieder S.

Leukemia. 2016 Apr;30(4):823-32. doi: 10.1038/leu.2015.329. Epub 2015 Dec 1.

PMID:
26621336
16.

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.

Chatain N, Perera RC, Rossetti G, Rossa J, Carloni P, Schemionek M, Haferlach T, Brümmendorf TH, Schnittger S, Koschmieder S.

Leukemia. 2015 Dec;29(12):2434-8. doi: 10.1038/leu.2015.131. Epub 2015 May 27. No abstract available.

PMID:
26012842
17.

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.

Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B, Hiddemann W, Berdel WE, Brümmendorf TH, Müller-Tidow C, Koschmieder S.

PLoS One. 2015 May 21;10(5):e0125783. doi: 10.1371/journal.pone.0125783. eCollection 2015.

18.

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.

Kirschner MM, Schemionek M, Schubert C, Chatain N, Sontag S, Isfort S, Ortiz-Brüchle N, Schmitt K, Krüger L, Zerres K, Zenke M, Brümmendorf TH, Koschmieder S.

PLoS One. 2015 Apr 20;10(4):e0123476. doi: 10.1371/journal.pone.0123476. eCollection 2015.

19.

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.

Jost E, Lin Q, Weidner CI, Wilop S, Hoffmann M, Walenda T, Schemionek M, Herrmann O, Zenke M, Brümmendorf TH, Koschmieder S, Wagner W.

Leukemia. 2014 Jun;28(6):1227-34. doi: 10.1038/leu.2013.362. Epub 2013 Nov 27.

20.

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T.

Blood. 2013 May 16;121(20):4175-83. doi: 10.1182/blood-2012-11-466938. Epub 2013 Mar 29.

21.

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Lipka DB, Wagner MC, Dziadosz M, Schnöder T, Heidel F, Schemionek M, Melo JV, Kindler T, Müller-Tidow C, Koschmieder S, Fischer T.

PLoS One. 2012;7(7):e40853. doi: 10.1371/journal.pone.0040853. Epub 2012 Jul 16.

22.

Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML.

Schemionek M, Spieker T, Kerstiens L, Elling C, Essers M, Trumpp A, Berdel WE, Müller-Tidow C, Koschmieder S.

Leukemia. 2012 May;26(5):1030-7. doi: 10.1038/leu.2011.366. Epub 2011 Dec 23.

PMID:
22193968
23.

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.

Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19.

24.

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.

Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S, Gerss J, Maecker HT, Berdel WE, Juergens H, Lee PP, Rossig C.

Leukemia. 2012 Mar;26(3):465-74. doi: 10.1038/leu.2011.239. Epub 2011 Sep 9.

PMID:
21904381
25.

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.

Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hofmann WK, Berdel WE, Müller-Tidow C, Reiter A, Koschmieder S.

Blood. 2011 Mar 10;117(10):2935-43. doi: 10.1182/blood-2010-05-286757. Epub 2011 Jan 11.

PMID:
21224473
26.

Mouse models as tools to understand and study BCR-ABL1 diseases.

Koschmieder S, Schemionek M.

Am J Blood Res. 2011;1(1):65-75. Epub 2011 Jun 7.

27.

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Schemionek M, Elling C, Steidl U, Bäumer N, Hamilton A, Spieker T, Göthert JR, Stehling M, Wagers A, Huettner CS, Tenen DG, Tickenbrock L, Berdel WE, Serve H, Holyoake TL, Müller-Tidow C, Koschmieder S.

Blood. 2010 Apr 22;115(16):3185-95. doi: 10.1182/blood-2009-04-215376. Epub 2010 Jan 6.

28.

Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells.

Myssina S, Helgason GV, Serrels A, Jørgensen HG, Bhatia R, Modi H, Baird JW, Mountford JC, Hamilton A, Schemionek M, Koschmieder S, Brunton VG, Holyoake TL.

Exp Hematol. 2009 Feb;37(2):206-14. doi: 10.1016/j.exphem.2008.10.013. Epub 2008 Dec 18.

PMID:
19100678
29.

PslD is a secreted protein required for biofilm formation by Pseudomonas aeruginosa.

Campisano A, Schroeder C, Schemionek M, Overhage J, Rehm BH.

Appl Environ Microbiol. 2006 Apr;72(4):3066-8.

30.

Expression of the psl operon in Pseudomonas aeruginosa PAO1 biofilms: PslA performs an essential function in biofilm formation.

Overhage J, Schemionek M, Webb JS, Rehm BH.

Appl Environ Microbiol. 2005 Aug;71(8):4407-13.

Supplemental Content

Loading ...
Support Center